BETHESDA, Md., Feb. 8 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (OTC Bulletin Board: NWBO), a development stage biotechnology company focused on personalized cancer vaccines to enhance immune system responses to tumors, has retained Market Media Connect as their communications agency of record. Led from its Los Angeles headquarters, Market Media Connect will support Northwest's communication objectives as the company moves into the next phase of its development.
"We have spent over a decade developing our technologies and advancing our clinical programs," said Dr. Alton Boynton, Chief Executive Officer of NWBO. "As we continue our own development, and as immune therapies for cancer come of age, we need a well-established agency with a broad base of expertise to help us communicate effectively about our vaccines, our clinical progress and the underlying scientific support. We are confident Market Media Connect is the right agency partner to help us reach the next level in our communication efforts."
Currently approved cancer treatments are frequently ineffective, cause undesirable toxic side effects and provide limited clinical benefits. In its novel cancer therapies, Northwest Biotherapeutics mobilizes dendritic cells ('DCs'), which are the master cells of the immune system. Northwest Biotherapeutics' lead products are proprietary dendritic cell vaccines for prostate and brain cancer.
"Northwest Biotherapeutics is well positioned to transform the way the biotech community views cancer treatments," said James Morham, CEO of Market Media Connect. "We look forward to working in tandem with Northwest Biotherapeutics to expand and strengthen their external communications and visibility."
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, without toxicities of the kinds associated with chemotherapies, and on a cost-effective basis. The Company has two broad platform technologies: dendritic cell-based vaccines and therapeutic antibodies. The Company is focusing on development of its dendritic cell vaccines. The Company's lead clinical trial is a 240 patient double blind, randomized, placebo controlled Phase II trial in newly diagnosed Glioblastoma Multiform ("GBM"), the most lethal form of brain cancer. The Company has also received clearance from the FDA for a 600+ patient Phase III trial in prostate cancer, and clearance from the FDA for Phase I trials in five other cancers. These programs will require a ramp-up period following additional funding. The Company is also conducting a Phase I/II trial with DCVax® for recurrent metastatic ovarian cancer. The Company's second technology platform, involving antibodies to CXCR4, is at the late pre-clinical development stage. For further information about clinical sites and Company information please visit the company web site at www.nwbio.com.
About Market Media Connect
Market Media Connect was formed to help shine extensive media attention on publicly traded companies who are helping to change the world with innovative, news making technologies. Market Media Connect uses public relations and electronic media to highlight successes of the companies it partners with in order to deliver that information to the investment community as well as traditional print and electronic media. Market Media Connect was founded by James Morham, an industry leader in print, radio, broadcast and television advertising whose decades of experience in the field include management stints at Charter Communications and Time Warner.
SOURCE Market Media Connect
|SOURCE Market Media Connect|
Copyright©2010 PR Newswire.
All rights reserved